Stay up to date on the latest oncology and nursing conferences.
Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL
January 11th 2023Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.
POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast Cancer
January 6th 2023Jamie Carroll, APRN, CNP, MSN, weighs in on how findings from the POSITIVE study may change dialogue surrounding pregnancy for women with estrogen receptor–positive breast cancer who wish to pause adjuvant therapy.
Antidiarrheal Prophylaxis Remains a Key Focus in TKI Treatment for Patients with HER2+ Breast Cancer
January 4th 2023Loperamide prophylaxis was linked to low rates of grade 3 diarrhea in patients receiving adjuvant pyrotinib, but better antidiarrheal prophylaxis options are still needed in this setting.
Second-Line Liso-Cel Continues to Improve Event-Free Survival in Large B-Cell Lymphoma
December 25th 2022In the second line setting, lisocabtagene maraleucel (liso-cel; Breyanzi) significantly reduced the risk of an event for patients with high-risk relapsed/refractory large B-cell lymphoma, compared with standard-of-care chemoimmunotherapy induction.
Ovarian Suppression Treatment Is Rare for Premenopausal Women with HR+/HER2+ Breast Cancer
December 12th 2022In real-world practice, use of ovarian suppression therapy was not common among premenopausal patients with hormone receptor–positive, HER2-positive breast cancer, with tamoxifen being the preferred endocrine therapy.
Real-World Patient-Reported Outcomes for Axi-Cel Align With Clinical Trial QOL, Symptomology Data
December 11th 2022Real-world data from patient-reported outcomes suggest that axicabtagene ciloleucel is associated with temporary worsening of quality of life with statistically and clinically significant improvements within 1-year postinfusion.